Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
8.0944 EUR
14.36 B EUR
43.94 B EUR
1.75 B
About NOVARTIS N
Sector
CEO
Vasant Narasimhan
Headquarters
Basel
Website
Founded
1996
ISIN
CH0012005267
FIGI
BBG000P33Q04
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where NOT is featured.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on DUS exchange NOVARTIS NAM. SF 0,49 stocks are traded under the ticker NOT.
We've gathered analysts' opinions on NOVARTIS NAM. SF 0,49 future price: according to them, NOT price has a max estimate of 126.41 EUR and a min estimate of 88.74 EUR. Watch NOT chart and read a more detailed NOVARTIS NAM. SF 0,49 stock forecast: see what analysts think of NOVARTIS NAM. SF 0,49 and suggest that you do with its stocks.
Yes, you can track NOVARTIS NAM. SF 0,49 financials in yearly and quarterly reports right on TradingView.
NOVARTIS NAM. SF 0,49 is going to release the next earnings report on Jan 31, 2025. Keep track of upcoming events with our Earnings Calendar.
NOT earnings for the last quarter are 1.85 EUR per share, whereas the estimation was 1.74 EUR resulting in a 6.27% surprise. The estimated earnings for the next quarter are 1.75 EUR per share. See more details about NOVARTIS NAM. SF 0,49 earnings.
NOVARTIS NAM. SF 0,49 revenue for the last quarter amounts to 11.52 B EUR, despite the estimated figure of 11.49 B EUR. In the next quarter, revenue is expected to reach 12.39 B EUR.
NOT net income for the last quarter is 2.93 B EUR, while the quarter before that showed 3.05 B EUR of net income which accounts for −3.95% change. Track more NOVARTIS NAM. SF 0,49 financial stats to get the full picture.
Yes, NOT dividends are paid annually. The last dividend per share was 3.43 EUR. As of today, Dividend Yield (TTM)% is 3.70%. Tracking NOVARTIS NAM. SF 0,49 dividends might help you take more informed decisions.
NOVARTIS NAM. SF 0,49 dividend yield was 3.89% in 2023, and payout ratio reached 51.36%. The year before the numbers were 3.83% and 105.08% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Jan 22, 2025, the company has 76.06 K employees. See our rating of the largest employees — is NOVARTIS NAM. SF 0,49 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NOVARTIS NAM. SF 0,49 EBITDA is 19.10 B EUR, and current EBITDA margin is 44.33%. See more stats in NOVARTIS NAM. SF 0,49 financial statements.
Like other stocks, NOT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NOVARTIS NAM. SF 0,49 stock right from TradingView charts — choose your broker and connect to your account.